Biomedical Engineering Reference
In-Depth Information
Grabowski HG, Vernon JM (1992) Brand loyalty, entry, and price competition in pharmaceuticals
after the 1984 Drug Act. J Law Econ 35(2):331-350
Grabowski HG, Kyle MK (2007) Generic competition and market exclusivity periods in pharma-
ceuticals. Manag Decis Econ 28(4-5):491-502
Hassali MAA, Shafi e AA, Jamshed S, Ibrahim MIM, Awaisu A (2009) Consumers' views on
generic medicines: a review of the literature. Int J Pharm Pract 17(2):79-88
Hellerstein JK (1998) The importance of the physician in the generic versus trade-name prescrip-
tion decision. Rand J Econ 29(1):108-136
Hemphill CS, Sampat BN (2011) When do generics challenge drug patents? J Empir Leg Stud
8(4):613-649
Herrick TM, Million RP (2007) Tapping the potential of fi xed-dose combinations. Nat Rev Drug
Discov 6(7):513-514
Higgins MJ, Graham SJH (2009) Balancing innovation and access: patent challenges tip the scales.
Science 326(5951):370-371
Hollis A (2003) The anticompetitive effects of brand-controlled 'pseudo-generics' in the Canadian
pharmaceutical market. Can Public Policy 29(1):21-32
Hong SH, Shepherd MD, Scoones D, Wan TTH (2005) Product-line extensions and pricing strate-
gies of brand-name drugs facing patent expiration. J Manag Care Pharm 11(9):746-754
Hudson J (2000) Generic take-up in the pharmaceutical market following patent expiry: A multi-
country study. Int Rev Law Econ 20(2):205-221
Hurwitz MA, Caves RE (1988) Persuasion or information? Promotion and the shares of brand
name and generic pharmaceuticals. J Law Econ 31(2):299-320
Huskamp HA, Donohue JM, Koss C, Berndt ER, Frank RG (2008) Generic entry, reformulations,
and promotion of SSRIs. Pharmacoeconomics 26(7):603-616
Iizuka T (2004) What explains the use of DTCA of prescription drugs? J Ind Econ
52(3):349-379
Kadiyali V, Vilcassim NJ, Chintagunta PK (1996) Empirical analysis of competitive product line
pricing decisions: lead, follow, or move together? J Bus 69(4):459-487
Kamien MI, Zang I (1999) Virtual patent extension by cannibalization. South Econ J
66(1):117-131
Kong Y, Seldon JR (2004) Pseudo-generic products and barriers to entry in pharmaceutical mar-
kets. Rev Ind Organ 25(1):71-86
Königbauer I (2007) Advertising and generic entry. J Health Econ 26(2):286-305
Kozlowski S, Woodcock J, Midthun K, Sharman RB (2011) Developing the nation's biosimilars
program. N Engl J Med 365(5):385-388
Kvesic DZ (2008) Product lifecycle management: marketing strategies for the pharmaceutical
industry. J Med Market 8(4):293-301
Kvesic DZ (2009) Adalat: a lifecycle managed. J Med Market 9(3):187-200
Landes WM, Posner RA (1987) Trademark law: an economic perspective. J Law Econ
30(2):265-309
Lexchin J (2004) The effect of generic competition on the price of brand-name drugs. Health Aff
68(1):47-54
Ling DC, Berndt ER, Kyle MK (2002) Deregulating direct-to-consumer marketing of prescription
drugs: effects on prescription and over-the-counter product sales. J Law Econ 45(2):691-723
Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov
8(12):959-968
O'Connor KA, Roth BL (2005) Finding new tricks for old drugs: an effi cient route for public-
sector drug discovery. Nat Rev Drug Discov 4(12):1005-1014
Parece A, Tuttle E, Hector A (2004) Your patent is about to expire: what now? Pharm Exec
24(11):88-98
Regan TL (2008) Generic entry, price competition, and market segmentation in the prescription
drug market. Int J Ind Organ 26(4):930-948
Reiffen D, Ward MR (2005) Generic drug industry dynamics. Rev Econ Stat 87(1):37-49
Search WWH ::
Custom Search